Review of Cardiotoxicity in Pediatric Cancer Patients: During and after Therapy by Fulbright, Joy M.
SAGE-HindawiAccess to Research
Cardiology Research and Practice
Volume 2011, Article ID 942090, 9 pages
doi:10.4061/2011/942090
Review Article
Review ofCardiotoxicityinPediatric Cancer Patients:
During and afterTherapy
Joy M. Fulbright
Division of Pediatric Hematology/Oncology, Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA
Correspondence should be addressed to Joy M. Fulbright, jmfulbright@cmh.edu
Received 15 October 2010; Revised 31 January 2011; Accepted 17 March 2011
Academic Editor: Syed Wamique Yusuf
Copyright © 2011 Joy M. Fulbright. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Withtheimprovementinsurvivalfrom childhood cancer,lateeﬀects oftherapy are becomingmoreapparent.Cardiac disease,one
of these late eﬀects, has a signiﬁcant impact on the life of survivors of childhood cancers. Most survivors are followed by primary
care doctors andadultsubspecialists after they havegraduated from pediatric centers. Sincemuch ofthe cardiac toxicityoftherapy
occurs years oﬀ of therapy, it is important for these physicians to be aware of how to monitor survivors for the development of
cardiac toxicities. In this paper we will discuss the incidence of cardiac disease during treatment and in survivors, what treatment
modalities contribute to its development and modalities utilized to screen for cardiac disease. Recommendations for posttherapy
monitoringwill be emphasized.
1.Introduction
Treatment for pediatric malignancies has greatly improved
survival since the1970s.AccordingtoSEERdata,themortal-
ityratedeclinedbyalmost40percentbetween1975and1995
[1]. This decrease in mortality has been accompanied by an
increase in the recognition of long-term side eﬀects from
the treatment of childhood cancers. The Childhood Cancer
Survivor Study (CCSS) was established to monitor these side
eﬀects. The study has been following a cohort of patients,
who were treated from1970–1986and had survived at least 5
years at enrollment in the study [2]. This cohort of survivors
was found to have increased relative risk of a chronic health
conditioncomparedtotheirsiblings of3.3(95%CI,3.0–3.5)
[3]. Chronichealthcare conditionsattributedtocancertreat-
mentinclude,butare notlimited to,respiratory dysfunction,
infertility, cognitive delays, cardiovascular disease, and renal
failure[2,3].InasubanalysisoftheCCSSpopulation,14,358
patients returned a survey regarding cardiovascular health
[4]. Congestive heart failure had a prevalence of 1.7% versus
0.2% in siblings, valvular abnormities of 1.6% in survivors
versus 0.5% in siblings, and pericardial disease of 1.3% in
survivors versus 0.3% among siblings. This increase risk
highlights the need for survivors of childhood cancers to
be monitored for the development of cardiovascular disease
long term after treatment.
Please note that this is not a systematic review, but an
attempt to educate caregivers whose focus does not lie pri-
marily in the ﬁelds of hematology-oncology regarding the
pediatric cancer treatments which may place survivors at
risk for developing cardiac dysfunction. It also includes
recommendations for monitoring for the development of
cardiac dysfunction. This paper is comprised of published
data written in English which was compiled through Med-
line, with a focus on studies that included patients that
were under the age of 18 at time of their cancer treatment.
Due to the inclusion criteria, the reader should be aware of
apotentialbiasregarding negativestudyresultswhich areless
likely to be published.
2.RiskFactors
The treatment of children with cancer includes chemother-
apy, radiation, and surgery. Both chemotherapy and radia-
tion therapy can contribute to the increased risk for cardio-
vascular disease that survivors of childhood cancer experi-
ence (see Table 1).2 Cardiology Research and Practice
Table 1: Cancer therapies utilized in pediatric population associated with cardiotoxicity.
Type of therapy Dose that places at highest risk Time of usual presentation Cardiac manifestations
Radiation therapy [65] >30gray to heart Up to decades after treatment has
ended
Pericarditis, coronary
artery disease, valvular
disease, arrythmias
Anthracyclines [5, 7] >300mg/m2 doxorubicin
isotoxic cumulative dose
Acute: during therapy
Chronic: months to years
posttherapy (longer follow
higher the incidence)
Acute-arrythmias,
hypotension
Chronic-CHF
Cyclophosphamide [33, 34] >150mg/kg or >1.55g/m2 given
as one dose or per one course
ECG changes: 1–3 days after
therapy
CHF: up to 2 weeks after therapy
CHF, Myocarditis
Cytarabine [33, 34] High doses 3–28 days after initiation of
therapy
Pericarditis, ventricular,
and atrial arrythmias
Cisplatin [33, 34] Usually when receiving with
other chemotherapy
Arrythmias/hypotension: acute
within hours
Vascular toxicities: usually days
after infusion but reports 4 and
18mths post therapy
Arrythmias
Vascular toxicities (CVA,
AMI)
Ifosfamide [34, 41] Higher doses 6–23 days after ﬁrst dose CHF, arrythmias
CHF: Congestive Heart Failure, ECG: Electrocardiogram.
2.1. Anthracycline Therapy. Anthracyclines are the class of
chemotherapeutic agents that are most frequently linked
to cardiac dysfunction in children. The traditionally used
anthracyclines, doxorubicin, and daunorubicin were devel-
oped in the 1960s from the bacterial strain Streptomyces
peucetius [5]. After or during administration of an anthra-
cycline, patients can experience acute cardiac toxicity which
manifests as acute hypotension or transient rhythm dis-
turbances. This is usually transient and resolves without
intervention [6]. Early chronic and late onset chronic car-
diotoxicity manifests as a decrease in cardiac function which
can lead to congestive heart failure (CHF). This is thought
to be due to a decrease in left ventricular wall thickness,
indicating a decrease in cardiac tissue [7–10].
The incidence of cardiac dysfunction postanthracycline
therapy varies depending upon how cardiac dysfunction is
deﬁned and the length of time between the end of therapy
and evaluation [11, 12]. In a retrospective cohort study of
6,493 patients who had received therapy on pediatric oncol-
ogy trials with an anthracycline, Krischer et al. conﬁrmed
early cardiotoxicity (deﬁned as congestive heart failure,
abnormal measurements of cardiac function that prompted
therapy to be disrupted, or sudden death from a presumed
cardiac event) in 106 (1.6%) of the patients [13]. Van Dalen
et al. followed a cohort of 830 patients for a mean of 8.5
years after anthracycline therapy and found that the risk of
clinical heart failure was 2.5% [14]. Some studies evaluate
patients for subclinical cardiac disease, patients that are not
symptomatic from their cardiac dysfunction. In a systematic
review including 25 diﬀerent studies which each included
>50 pediatric patients treated with an anthracycline, the
reported frequency of subclinical cardiotoxicity varied from
0% to 57%. Recently De Caro et al. published a cross-
sectional study evaluating the presence of subclinical car-
diotoxicity in pediatric patients treated with anthracyclines.
Seventeen of the 55 patients (30%) were identiﬁed as having
subclinical heart disease, but this did not correlate with
alterations in the response of the cardiovascular system
to dynamic exercise evaluated by cardiopulmonary exercise
testing [15].
It has been well established that the development of con-
gestive heart failure can occur at any anthracycline dose, but
the risk for developmentincreases with increased cumulative
dose of anthracycline, especially doses ≥300mg/m2 [8, 13,
16–28].Ithasalsobeennotedthatthelongerithasbeensince
a patient has received anthracycline treatment the higher
their risk is for developing changes in cardiac function [10,
28, 29].
Earlier age at diagnosis and start of treatment with
anthracycline-based therapy has correlated with an increase
risk of cardiac disease in many studies that evaluated cardiac
function after completion of therapy [8, 19, 25, 29, 30].
However, not every study demonstrates this correlation as
notedinthesystematicreviewbyKremeretal.[11]andother
studies [24, 29, 31]. These studies involve small number of
patients from 80–265. A larger study that evaluated 6,493
patients during therapy found that age at time of diagnosis
was not a statistically signiﬁcant predictor of cardiotoxicity,
though children less than 9 had an increase risk of sudden
deathorCHF[13].Ingeneralexpertpanelshaverecommend
that patients who receive anthracycline therapy at an earlier
age are monitored more closely for development of cardiac
disease.
Female gender has also been associated with increased
risk for cardiac disease in several studies [9, 13, 16, 32]. The
reason female gender has been correlated with this increased
risk is unknown. Lipshultz et al. hypothesized that it may be
due to “diﬀerences in oxidative stress, diﬀerential expression
of the multidrug-resistance gene, and body composition’’
[9]. As with age, there are some studies that do not echo
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female sex as predictive factor for CHF was the study by
Kirscher et al. As stated above this study evaluated the
occurrence of cardiotoxicity during therapy. 585 out of the
6,493patients receivedradiation totheheart which may have
inﬂuenced some of their results [13]. Green et al. also found
the correlation between female sex and development of
cardiotoxicity in their case control study of 2,710 treated for
Wilms tumor. In this study “the risk for girls was estimated
to be approximately four times that for boys with the same
level of cumulative doxorubicin exposure and radiation to
the lung and the left abdomen (P, .005)” [16]. This leaves
the questionof whether radiation may be contributing to the
increase rate of cardiotoxicity in females in these studies.
2.2. Other Chemotherapeutic Agents. Other chemotherapy
agents that have cardiotoxic side eﬀects include cyclophos-
phamide, ifosfamide, cytarabine, and cisplatin. Paclitaxel,
ﬂuorouracil,and amsacrine also havecardiotoxicsideeﬀects,
but are rarely used in the ﬁrst-line treatment of pediatric
tumors [33, 34]. Newer agents, such as tyrosine kinase
i n h i b i t o r s ,h a v ea l s ob e e nf o u n dt ob ec a r d i o t o x i c[ 35–37].
For extensive review of cardiotoxic chemotherapeutic agents
please refer to the review by Pai and Nahata [34].
Cyclophosphamide, an alkylating agent, can produce
CHF or myocarditis. These symptoms are usually present
by 14 days after therapy [34]. Cyclophosphamide is rarely
cardiotoxic at low/standard doses but can cause severe car-
diotoxicity when administereda th i g hd o s e s ,s u c ha sw h e n
usedformyeloablation instemcelltransplant[38,39].When
Goldberg et al. recalculated the normal dose in mg/kg that is
given during transplant as dose per m2, patients with higher
dose per m2 have an increased risk for cardiotoxicity. It
was also noted that patients less than age 12 had far less
cardiotoxicity compared to older patients, though younger
patientstendedtoreceivealowerdose/m2 thanolderpatients
[38]. The advantage to Goldberg study, though it had a small
sample size of 84, is that the patients had not received
other cardiotoxic therapy such as anthracycline therapy or
radiation. The incidence of CHF in Golderbergs study was
0/32 in patients receiving ≤1.55g/m2 and 6/52 in patients
receiving >1.55g/m2. Van der Pal et al. evaluated a cohort
of601 patients of which 514 had evaluableechocardiograms.
164ofthesepatientsreceived <10g/m2 ofcyclophosphamide
and 60 received >10g/m2. Their analysis did not ﬁnd
a correlation between high doses of cyclophosphamide and
decreaseinleftventricularshortening fraction, butthiscould
be due to the fact that all but 10 of the patients also received
other cardiotoxic therapy.
Ifosfamide, also an alkylating agent, can illicit congestive
heart failure or arrhythmias [34, 40–42]. CHF usually occurs
within 6–23 days after initiation of ifosfamide and the
risk of CHF is generally thought to increase with higher
dose delivery of the medication [41, 42], though, as with
cyclophosphamide,studybyvanderPaletal.didnotsupport
this correlation.
After administration of cytarabine, an antimetabolite,
patients are also at risk for cardiac complications. Review
of the literature also reveals case reports of pericarditis
associated with the administration of cytarabine [43–45].
It is also associated with atrial and ventricular arrhythmias
along with CHF [33, 46–48]. These complications are rare
and associated with administration of high doses.
Cisplatin has been reported to be associated with ar-
rhythmias in several case reports [49–52]. Most of these
reports were in patients receiving cisplatin in combination
with other chemotherapeutic drugs. Cisplatin decreases
levelsofcalciumand magnesium, both ofwhich can increase
the risk for arrhythmias if not corrected [33]. There have
been case reports of vascular toxicity and acute myocardial
infarctions/cerebral vascular accidents with the administra-
tion of cisplatin, speciﬁcally as part of the treatment of germ
cell tumors [53–57] .T h er a r eo c c u r r e n c eo fv a s c u l a ra c c i -
dents should not deter clinicians from using this eﬃcacious
drug,buteveninyoungpatientsoneneedstoconsidervascu-
lar toxicitiesin a diﬀerential diagnosis of a patient presenting
with consistent symptoms following cisplatin therapy [54].
Tyrosine kinase inhibitors includedrugs such as imatinib
and sunitinib. Imatinib (Gleevec) is the most well-known
tyrosine kinaseinhibitorandisusedmainlyforthetreatment
ofchronic myelogenousleukemia,butmore recentlyhas also
been used in phase I and II studies treating relapsed solid
tumors [58–61]. Tyrosine kinase inhibitors as a drug class
have been linked with development of left ventricular dys-
function, heart failure, and arrhythmias [35, 37, 62]. These
events have been rarely reported with imatinib [63, 64],
but the incidence of symptomatic events in patients treated
with sunitinib or sorafenib was 18% in an observational
study of 74 patients [62]. This emphasizes the importance
of closely monitoring patients for the development of
cardiotoxicity when treating them with a tyrosine kinase
inhibitor, especially if they haveprevious cardiac disease, risk
factors for the development of cardiac dysfunction, or if one
is employing a newer, less studied tyrosine kinase inhibitor.
There are no speciﬁc guidelines for monitoring patients
treated with chemotherapy drugs besides, anthracyclines,
likely due to the relatively low frequency of these events.
Providers should be aware that cyclophosphamide, ifos-
famide, cytarabine, cisplatin, and tyrosine kinase inhibitors
may induce cardiotoxicity so that they can watch for signs
and symptoms of these events during and after treatment.
2.3. Radiation Therapy. Radiation therapy that is directed at
the mediastinum increases the risk for cardiovascular dam-
age and sequela postcancer therapy. Radiation to the medi-
astinum is most often utilized for the treatment ofHodgkin’s
lymphoma and breast cancer. Presentations of radiation
damage include pericarditis, cardiomyopathy, coronary
artery disease (which may lead to acute myocardial infarc-
tion), valvular disease, and conduction system arrythmias
[65,66].Pericarditisclinicallypresentseitherassuddenonset
ofpleuritic chest pain, dyspnea, fever,and friction rub orcan
beclinicallysilent.OnECG(electrocardiogram),STsegment
elevation and/or T wave inversion can be seen. Patients
exposed to thoracic radiation can develop systolic and/or
diastolic dysfunction (with diastolic being more common)
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cardiomyopathies[67].Radiationprimarilyaﬀectsthemitral
and aortic valves [65, 68, 69] and presents with ﬁbrosis
with or without calciﬁcations [67]. Conduction system
arrhythmias can be early, which are usually transient or late,
occurring months to years after treatment. Late conduction
abnormalities include atrioventricular nodal bradycardia,
intranodal blocks, and all other types of heart block
[65, 67].
Incidence of radiation-induced cardiovascular damage
varies depending upon several variables including the end
point measured, time postcompletion of therapy, radiation
techniques, and dosing. Pericarditis prior to newer radiation
techniques was seen in up to 40% of the patients, but with
new techniques and attempt at lowering doses this incidence
has been greatly reduced [65]. In study by Carmel and
Kaplan the incidence of pericarditis in patients treated for
Hodgkins was reduced from 20% with whole pericardial
irradiation to 2.5% when subcarinal blocking was utilized
along with thin lung block technique [70]. Adams et al.
screened asymptomatic patients who were diagnosed with
Hodgkin’s disease prior to age 25 that were ≥5y e a r so u t
fromtherapywithECG,echocardiograms, andexercisestress
tests. The majority (41/47) of the patients received 36–
44gray of radiation. 42.6 percent of these patients had
a signiﬁcant valvular defect, 5/43 had ﬁndings suggestive
of systolic dysfunction, and 16/43 had ﬁndings suggestive
of diastolic dysfunction. 35/43 had conduction abnormal-
ities including sinus tachycardia and bradycardia [71]. In
pediatric studies evaluating patients that had received doses
of radiation ≤25gray the incidence of cardiac dysfunction
seen on echocardiograms or nuclear imaging were much
lowerrangingfrom0–2.5%[22,72,73].Inastudyevaluating
patients for death from cardiac dysfunction in patients who
were treated for Hodgkin’s disease 4/544 patients treated at
age<19diedfromvalvularheart disease, CHF,pericarditisor
cardiomegaly, 6/544 died from an acute myocardial infarc-
tion. All of the patients that died had received a radiation
dose of >30 gray. There were no deaths in the group of
patientstreatedatage<19thathadreceived<30gray[22,72–
74].
The factors that increase the risk of developing postra-
diation cardiotoxicity are the volume of the heart exposed
to the radiation beam, higher total dose of radiation
[66, 74], the length of followup time from radiation (the
farther out from therapy the more likely you will develop
cardiotoxicity), younger age at exposure and higher frac-
tionated dose [65, 75]. The majority of the trials involving
pediatric patients that evaluate for cardiac radiation toxicity
focus on Hodgkin’s disease survivors, have small sample
sizes, recruit patients postcompletion of therapy and include
patients treated with chemotherapy. Patient’s treated with
lung irradiation for solid tumors such as Ewing’s sarcoma
or Wilm’s tumor can experience an increased risk for car-
diac disease, though there are limited studies evaluating
cardiotoxicity in these subgroups [16, 31].
3.Monitoring
Patients receiving therapy that has potential cardiotoxicity
require close monitoring during and after therapy. The goal
of monitoring during therapy is to identify early signs of
cardiotoxicity in order to modify a patient’s therapeutic plan
so that the risks of further development of cardiac disease
are decreased. These modiﬁcations of therapy have to be
balanced with risk of decreasing antitumor eﬀect of the ther-
apy. Posttherapy patients may require life-long monitoring
for late cardiotoxic eﬀects, especially if they have received
mediastinal radiation or higher doses of anthracyclines.
The following is an analysis of several diﬀerent modalities
available for the monitoring of cardiotoxicity.
3.1. Echocardiogram. Echocardiograms are the most fre-
quently used modality in the screening for cardiac disease
during or after therapy. Echocardiograms are noninvasive
and readily available. They provide means to evaluate the
left ventricular ejection fraction (LVEF) along with systolic
and diastolic cardiac function. As per Altena et al., “diastolic
measurements are probably the most sensitive to early
changes in cardiac function [76].” Many studies also use the
measurement of fractional shortening (FS). In the only
published guidelines for monitoring therapy during anthra-
cyclinetreatment inpediatricpopulation[77]Steinherzetal.
recommended that a drop in FS by an absolute value of ≥10
percentile units or FS ≤ 29% be considered a signiﬁcant
deterioration of function [78]. The disadvantage of echocar-
diograms is that they are preload dependent for several of
the parameters and are dependent on the expertise and
interpretation of echocardiographist [76]. The question of
whetherdeclineincardiacfunctionduringtherapycorrelates
with long-term development of cardiac impairment still
remains [79]. In the evaluation of pericarditis echocardio-
grams provide information regarding long-term sequela of
this disorder such as development of a pericardial eﬀusion,
but may be normal in the setting of acute pericarditis
[80]. Echocardiograms also provide useful information after
radiation therapy by evaluating for valvular defects.
3.2. Radionuclide Angiocardiography (RNA) (Includes MUGA
and Radionuclide Ventriculography). RNA is considered the
gold standard for estimating LVEF. Unlike echocardiograms,
thereislowintraindividual and intraobservervariationwhen
obtainingandanalyzingresults,butonlylimitedinformation
regarding diastolic function is obtained. RNA’s also expose
patients to radiation [76]. Another concern with using LVEF
as a screening tool lies in its ability to accurately predict
which patients will go on to develop cardiac impairment
[76, 81]. Steinherz et al. included RNA testing along with
an echocardiogram as part of their recommendations for
monitoring for deterioration of function during anthracy-
cline therapy [78]. Despite these recommendations, RNAs
are notwidely utilized in protocolsenrolling pediatric cancer
patients for monitoring for cardiotoxicity of the therapy
[77]. In order to minimize confounding variables, it is
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atleast 3weeks after anthracycline therapy,when patients are
normothermic and have a hemoglobin greater than 9g/dL
[77].
3.3. Electrocardiograms (ECG). ECGs are a noninvasive, in-
expensive tool in the evaluation of conduction abnormalities
that may develop after radiation and during the administra-
tion of certain chemotherapeutic agents. In addition ECGs
can demonstrate signs of cardiomyopathies. They do not
provide any information regarding LVEF and interpretation
ofthestudyvariesbetweenobservers[76].There issomeevi-
dence to suggest that prolonged corrected QT intervals may
predict cardiac disease [82]. Forthe above reasons, obtaining
an ECG is recommended as part of monitoring for cardiac
dysfunction in some protocols and as part of long-term fol-
lowup.
3.4. Biomarkers. Due to the concern regarding the ability of
echocardiograms and RNAs to predict which patients will
go on to develop cardiac impairment during treatment
[76, 79, 81] and lack of sensitivity to detect early stages of
cardiomyopathy[83–85],therehasbeenmuchrecentinterest
in the use of biomarkers. Biomarkers include B-type natri-
uretic peptide (BNP), N-terminal pro-BNP (NT-pro-BNP),
cardiac troponin T (cTnT), and cardiac troponin I (cTnI).
Mavinkurve-Groothuis wrote a review regarding biomarkers
inthedetectionofpediatric anthracyclinecardiotoxicity.The
review included a total of 14 studies with patient numbers
ranging from 15–63 per study and time from last dose of
anthracycline until the evaluation point varying from imme-
diatelyuntil17.5years after therapy.These variations made it
diﬃcultfor theauthors to make recommendations regarding
the most sensitive method to use to detect cardiomyopathy,
and when the best timing for obtaining echocardiograms
and biomarkers is. Ultimately, it was concluded that there
was a signiﬁcant relation between elevated biomarkers and
cardiac dysfunction in 6 of the 14 studies [83]. Mavinkurve-
Groothuis et al. recently published a study on a cohort of
122 asymptomatic survivors, a large number compared to
previous studies of this type. None of the patients had an
elevated cTnT and 16 had elevated NT-pro-BNP levels [86].
The elevated NT-pro-BNP levels correlated with increased
dose of anthracycline received, but not with changes in ejec-
tion fraction.
It appears that biomarkers for cardiomyopathy may pro-
vide some clinical utility, but studies with larger number of
patients need to be performed. It will also be necessary to
seriallyfollowchildrenwithelevatedlevelslongterminorder
tomonitorthefuturedevelopmentofcardiomyopathyandto
determine best timing of biomarkers.
4.MonitoringduringTherapy
The only published guidelines for monitoring for cardiotox-
icity during therapy in pediatrics was published by Steinherz
et al. in 1992 [78]. These guidelines pertain speciﬁcally to
monitoring when anthracyclines are being administered or a
patient receives mediastinal radiation. Prior to the beginning
of therapy, ECG, echocardiogram, plus/minus RNA should
be collected. When the total anthracycline dose given is
<300mg/m2, an echocardiogram should be obtained be-
fore every other course of anthracycline administration.
Once a patient has received greater than 299mg/m2,a n
echocardiogram should be performed before every cycle of
anthracycline administration. The recommendation that is
currently not frequently followed [77] is the addition of
RNA once anthracycline dose is >399mg/m2 or >299mg/m2
and patient has received radiation therapy >1000cGY to
mediastinum.
5.LateEffectMonitoringRecommendations
The Children’s Oncology Group (COG) published the
most recent recommendations for long-term followup of
childhood cancer survivors on line at http://www.survi-
vorshipguidelines.org/ [87]. These recommendations give
detailed guidelines regarding frequency of monitoring based
on the age of exposure to anthracycline, total dose of
anthracycline received, and administration of potentially
cardiotoxic radiation therapy. Page 34 and 35 of the guide-
lines pertain particularly to the cardiac monitoring after
anthracycline dosage. In order to calculate total dose of
anthracyclineapatientreceived,onemustconvertthedoseto
doxorubicin isotoxic doses. Recommended conversions are
doxorubicin multiply the dose by 1; daunorubicin multiply
the dose by 0.833; epirubicin multiply the dose by 0.67;
idarubicin multiplythe dose by 5; mitoxantrone multiplythe
doseby4.ThesedoseconversionsarepertheCOGlong-term
followup guidelines, but there is “a paucity of literature” to
support the conversions. They are solely intended to be used
tobase monitoring on. Pages91and 92pertain speciﬁcally to
monitoring forcardiotoxicityafter radiationtherapy.Modal-
ities of monitoring include scheduled echocardiograms’s
(ECG), detailed history and physical exam. For timing of
echocardiograms orMUGA scan, please refer to Table 2.T h e
Scottish Intercollegiate Guidelines Network (SIGN) has also
developed long-term followup of survivors of childhood
cancer guidelines that were published online in 2004. They
recommend that echocardiograms are obtained at regular
intervals during treatment with anthracyclines and every
three years thereafter in patients who have received a modest
dose <250mg/m2. A detailed cardiac assessment should be
performed for survivors of childhood cancer who are preg-
nant or planning a pregnancy or who wish to take part in
competitivesports. Asfar asradiation theystatethat“health-
care professionals should be aware that mediastinal irradia-
tion over 30Gy is a risk factor for cardiac disease later in life
and monitoring is necessary.” Details of this monitoring are
not speciﬁcally given [88].
Another key component to long-term followup of pa-
tients is to screen for cardiovascular risk factors. This screen
includes a fasting lipid proﬁle, smoking history, family
history of early coronary artery disease in expanded ﬁrst
degree pedigree(Male ≤ 55y; Female ≤65y),bloodpressure
(BP) on 3 separate occasions interpreted for age/sex/height,
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Table 2: Timing of echocardiograms or MUGA scan postcancer therapy as per children’s oncology group long-term followupguidelines for
survivors of childhood, adolescent, and young adult cancers version 3.0 [87].
Age at treatment Radiation with potential
impact to the heart
Anthracycline dose converted to
doxorubicin isotoxic dose Recommended frequency
<1y e a ro l d
Yes Any Every year
No
<200mg/m2 Every 2 years
≥200mg/m2 Every year
1–4 years old
Yes Any Every year
No
<100mg/m2 Every 5 years
≥100 to <300mg/m2 Every 2 years
≥300mg/m2 Every year
≥5y e a r so l d
Yes
<300mg/m2 Every 2 years
≥300mg/m2 Every year
No
<200mg/m2 Every 5 years
≥200mg/m2 to <300mg/m2 Every 2 years
≥300mg/m2 Every year
Any age with decrease in serial function Every year
activity history [89]. Kavey et al. separates patients into
three stratiﬁcations high, moderate, and at risk. In general
cancer survivors are considered to be at risk for cardiovas-
cular disease, but if they have 2 or more risk factors, as
per above, they are considered to be at moderate risk. When
a patient is considered to be at moderate risk from at risk
the goal for LDL (low density lipoprotein) changes from
≤160mg/dl to <130mg/dl, BMI goal from ≤95% to ≤90%
and BP goal from ≤95% + 5mmHg to just <95%. Goal
for FG is <100mg/L and Hemoglobin A1c < 7% regardless
of risk stratiﬁcation. In general lifestyle modiﬁcations are
recommended if patients do not meet these goals with close
followup and then possible medications in the future to treat
hyperlipidemia and hypertension. In the case of FG > 125 an
endocrine referral needs to be made to initiate treatment for
diabetes mellitus. These recommendations were published
by the American Heart Association and endorsed by the
American Academy of Pediatrics.
6.Conclusion
Currently,thereisongoingresearch intodevelopingmethods
to deliver treatment for childhood cancers that reduce the
risk of developing long-term sequela from treatment. Diﬀer-
ent formulations of anthracyclines have been and continue
tobedevelopedthatare hopedto belesscardiotoxic.There is
clinical trial literature to support that liposomal doxorubicin
is less cardiotoxic than doxorubicin. Also, pretreatment
with dexrazoxane has been found to decrease the risk of
anthracycline-induced CHF, but most of these studies have
been performed in adults [90, 91]. Pediatric clinical trials
continue to be developedto evaluateif we can decrease doses
of cardiotoxic chemotherapeutic agents or reduce radiation
therapy doses in order to prevent long-term side eﬀects
from the therapy without decreasing survival. Hodgkin’s
lymphoma is a good example of this. Doses of radiation
administered in modern trials have been greatly reduced.
The most recently closed COG trial for intermediate risk
Hodgkin’slymphomaevaluatedwhetherornotradiationcan
be eliminated based on response to multiagent chemother-
apy.
Until we can eliminate the cardiotoxic side eﬀects of
treatment for pediatric cancers it is important that clinicians
providing care to survivors are aware of the potentially
cardiotoxic treatments their patients have received and to
be well versed in the methods used in the detection of
cardiotoxic developments. This is to try and initiate early
treatment and hopefully reduce worsening of symptoms.
Well-designed prospective studies that evaluate monitoring
modalities and the frequency at which monitoring should
occur have yet to be published. There are online guidelines
available that are based on review of the current literature
and expert opinion. The COG and SIGN have published
guidelines that are accessible to clinicians and families for
reference online at http://www.survivorshipguidelines.org/
and http://www.sign.ac.uk/guidelines/fulltext/76/index.html
[88]. These are not to take place of clinical judgment, but to
serveasagoodstartingpointfordesigningamonitoringplan
[87]. Patients need also to be made aware of their risk so that
they can implement lifestyle modiﬁcations that will decrease
their risk of developmentof cardiac disease.
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